Graft and Grit
Live
Stages

IntelliProve secures €2.7 million to scale camera-based health monitoring

Belgian healthtech startup IntelliProve raised €2.7 million in a 2023 seed round led by Miles Ahead. The funding will scale its smartphone-camera health monitoring software and expand into humanoid robotics.

Stages: Belgian healthtech startup IntelliProve raised €2.7 million in a 2023 seed round led by Miles Ahead

IntelliProve raised €2.7 million in a 2023 seed funding round. The Belgian healthtech startup will use the capital to scale its camera-based health monitoring technology globally. The round was led by the early-stage fund Miles Ahead, which manages €30 million. Participants included Wit-Gele Kruis, imec.istart, and several business angels. This marks the company's third announced funding round, following a €1 million raise in November 2022 and a €1.25 million round in January 2025, both also led by Miles Ahead.

Technology and validation

IntelliProve develops software that measures health indicators using the standard cameras in smartphones, laptops, and other devices. Its technology uses remote photoplethysmography (rPPG). This method detects subtle skin colour changes caused by blood circulation and breathing movements. A 30-second facial scan provides six key biomarkers.

The company's models have been tested and validated on a dataset of more than six million data points. The software is designed to work across diverse skin tones, ages, lighting conditions, and camera types without requiring extra hardware. IntelliProve built its solution on three core technologies: VitalMesh, which tracks facial skin during movement; TripleGate, which monitors signal quality; and PulseShape, which uses deep learning for vital signs estimation.

Market need and scalability

Healthcare systems worldwide are under strain. Ageing populations and staff shortages are intensifying demand for care. Traditional health monitoring requires dedicated equipment and professional assistance, which limits scalability. IntelliProve's hardware-free approach aims to address this gap. The company collaborates with research institutions like TU Delft and Ghent University Hospital to advance its technology.

The global remote patient monitoring systems market reflects this growing need. It was valued at $26 billion in 2025 and is projected to reach $110.7 billion by 2033. This represents a compound annual growth rate of 20% from 2026 to 2033. IntelliProve's solution is already integrated into virtual care, health insurance, and wellbeing platforms in more than 50 countries. The company also holds ISO 27001 certification for information security.

Expansion and regulatory path

The new funding will drive expansion into new hardware categories. IntelliProve plans to integrate its face-scan technology into humanoid and assistive robots, smart glasses, and self-service kiosks. This move targets health monitoring in private homes and care facilities. A key strategic focus is advancing clinical validation and securing regulatory approval.

The company is pursuing CE marking as a Class IIa medical device under the European Union's Medical Device Regulation. Achieving this certification is a central goal for the capital. The funding will also support expanding clinical datasets across more skin tones, age groups, and devices. Research to improve measurement accuracy and pursue certification beyond Europe will continue.

IntelliProve was founded in 2021 by Joeri Tulkens, Tanguy Sanglet, Brecht Dhuyvetters, and Maxime Mattelin. Tulkens serves as co-founder and co-CEO, while Sanglet is co-founder and CTO. The healthtech sector is competitive. Other players include Binah.ai, which raised a $13.5 million Series B in June 2020; YOU(th) Health Tech, which secured $4.5 million in February 2026; smedo, with a €1.66 million seed round in April 2022; and Hilo, which closed a $19 million Series B extension in July 2026. IntelliProve will now use its fresh capital to advance clinical validation and seek Class IIa medical device certification under EU regulations.

Topics

#Seed

Related coverage

More from Stages